DOM-SERTRALINE CAPSULE

Country: Канада

Језик: Енглески

Извор: Health Canada

Активни састојак:

SERTRALINE (SERTRALINE HYDROCHLORIDE)

Доступно од:

DOMINION PHARMACAL

АТЦ код:

N06AB06

INN (Међународно име):

SERTRALINE

Дозирање:

100MG

Фармацеутски облик:

CAPSULE

Састав:

SERTRALINE (SERTRALINE HYDROCHLORIDE) 100MG

Пут администрације:

ORAL

Јединице у пакету:

100

Тип рецептора:

Prescription

Терапеутска област:

SELECTIVE-SEROTONIN REUPTAKE INHIBITORS

Резиме производа:

Active ingredient group (AIG) number: 0123417002; AHFS:

Статус ауторизације:

APPROVED

Датум одобрења:

2002-05-31

Карактеристике производа

PRODUCT MONOGRAPH
Pr
DOM-SERTRALINE
Sertraline Hydrochloride Capsules
25 mg, 50 mg and 100 mg
Sertraline (as sertraline hydrochloride)
ANTIDEPRESSANT / ANTIPANIC / ANTIOBSESSIONAL AGENT
DOMINION PHARMACAL
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
DATE OF REVISION:
May 15, 2018
Submission Control No: 215667
_Dom-SERTRALINE Product Monograph _
_Page 2 of 52_
PRODUCT MONOGRAPH
PR
DOM-SERTRALINE
Sertraline Hydrochloride Capsules
25 mg, 50 mg and 100 mg
Sertraline (as sertraline hydrochloride)
THERAPEUTIC CLASSIFICATION
Antidepressant - Antipanic - Antiobsessional Agent
ACTION AND CLINICAL PHARMACOLOGY
The mechanism of action of sertraline is presumed to be linked to its
ability to inhibit the neuronal
reuptake of serotonin. It has only very weak effects on norepinephrine
and dopamine neuronal
reuptake. At clinical doses, sertraline blocks the uptake of serotonin
into human platelets.
Like most clinically effective antidepressants, sertraline
downregulates brain norepinephrine and
serotonin receptors in animals. In receptor binding studies,
sertraline has no significant affinity for
adrenergic (
_alpha_
_1_
_, alpha_
_2_
_ & beta_
), cholinergic, GABA, dopaminergic, histaminergic, serotonergic
(5-HT1A, 5-HT1B, 5-HT2) or benzodiazepine binding sites.
In placebo-controlled studies in normal volunteers, sertraline
hydrochloride did not cause sedation
and did not interfere with psychomotor performance.
Pharmacokinetics: Following multiple oral once-daily doses of 200 mg,
the mean peak plasma
concentration (C
max
) of sertraline is 0.19 mcg/mL occurring between 6 to 8 hours
post-dose. The
area under the plasma concentration time curve is 2.8 mg hr/L. For
desmethylsertraline, C
max
is
0.14 mcg/mL, the half-life 65 hours and the area under the curve 2.3
mg hr/L. Following single or
multiple oral once-daily doses of 50 to 400 mg/day the average
terminal elimination half-life is
approximately 26 hours. Linear dose proportionality has been
demonstrated over the clinical dose
range of 50 to 200 mg/day.
Food appe